Drug
Nazartinib clinical trials
Also written EGF816.
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
Novartis Pharmaceuticals (6) · University of Cologne (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Trametinib (2) · Capmatinib (2) · Spartalizumab (1) · Canakinumab (1) · CJM-112 (1) · Batoprotafib (1) · Gefitinib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses nazartinib is read from its arms, and is right about nine times in ten.
Testing it · 8
- Dose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsTerminatedPhase 1Novartis PharmaceuticalsNCT03114319Written as TNO155 in combination with EGF816 (nazartinib)
- A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung CancerTerminatedPhase 2Massachusetts General HospitalNCT03292133Written as EGF816
- A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid MalignanciesCompletedPhase 1/2Novartis PharmaceuticalsNCT02108964Written as EGF816
- EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR MutationsCompletedPhase 1University of CologneNCT03516214Written as EGF816
- Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.TerminatedPhase 1/2Novartis PharmaceuticalsNCT02335944Written as Nazartinib
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedPhase 1Novartis PharmaceuticalsNCT02900664Written as EGF816
- Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerTerminatedPhase 2Novartis PharmaceuticalsNCT02323126Written as EGF816
- Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating MutationsWithdrawnPhase 3Novartis PharmaceuticalsNCT03529084Written as EFG816
Given in every arm · 2 — nazartinib is usual care beside what is tested
- Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneActive, not recruitingPhase 2Novartis PharmaceuticalsNCT03040973Written as Nazartinib
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingPhase 1Novartis PharmaceuticalsNCT03333343Written as EGF816
Codes
What other systems call nazartinib · ClinicalTrials.gg INT000689
- MeSH (NLM) C000619734nazartinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) KE7K32EME8NAZARTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27087855nazartinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C115109NazartinibOne source FDA
- DrugBank DB16250One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619734 | nazartinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | KE7K32EME8 | NAZARTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27087855 | nazartinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C115109 | Nazartinib | One source FDA |
| DrugBank | DB16250 | — | One source Wikidata |
Also registered as nazartinib mesylate (UNII T0ECU9IJ0N).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.